BioCentury | Mar 19, 2021
Product Development

Point’s SPAC, Aktis’ A round add to cash flow for radiotherapies: Data Byte

...million in a 2019 series B round, and another $213 million in an IPO last June.RayzeBio Inc....
...ASA (OSE:NANOV) raised $53 million on the public markets. Karen Tkach Tuzman Point Biopharma Inc. Aktis Oncology Fusion Pharmaceuticals Inc. RayzeBio Inc. Actinium...
BioCentury | Mar 18, 2021
Emerging Company Profile

Through Aktis, MPM bets on radiotherapy for solid tumors

...demand to do another round, even before getting into patients.”A surge of investor appetite enabled competitor RayzeBio Inc....
...Crossover, Novartis AG (NYSE:NVS; SIX:NOVN), Bristol Myers Squibb Co. (NYSE:BMY)CEO: Matthew RodenPatents: Undisclosed Karen Tkach Tuzman MPM Capital RayzeBio Inc. atkis...
BioCentury | Mar 17, 2021
Management Tracks

High-profile departures at Sage, bluebird as Cloonan, Davidson depart; plus CBC Group, Turning Point, Agilent, Intercept, Centessa, Beam and more

...CEO and a member of board. Most recently Knickerbocker cofounded and served as CEO at RayzeBio Inc....
BioCentury | Jan 8, 2021
Finance

Venrock stays modest with $450M ninth fund as it continues to seek disruptive, early-stage tech

...will be allocated to healthcare, and the remainder to technology. Recent therapeutics investments include targeted radiotherapy play RayzeBio Inc....
BioCentury | Dec 18, 2020
Product Development

2021 Predictions: a BioCentury survey

...also garnered substantial investor interest. This month, RayzeBio Inc....
BioCentury | Dec 12, 2020
Finance

RayzeBio gets unexpected lift from broad investor appetite for targeted radiotherapies

...Capital.Versant’s Jerel Davis said the firm scouted radiotherapy opportunities for three years before investing in RayzeBio Inc. Versant...
...operations.Bong Koh, the lead investor from Venrock Healthcare Capital Partners, is joining RayzeBio’s board. Karen Tkach Tuzman RayzeBio Inc. radiophramaceuticals radiotherapy targeted...
BioCentury | Oct 15, 2020
Emerging Company Profile

RayzeBio pulling together radiotherapy platform with $45 million

...Song told BioCentury he was drawn to RayzeBio Inc....
Items per page:
1 - 7 of 7
BioCentury | Mar 19, 2021
Product Development

Point’s SPAC, Aktis’ A round add to cash flow for radiotherapies: Data Byte

...million in a 2019 series B round, and another $213 million in an IPO last June.RayzeBio Inc....
...ASA (OSE:NANOV) raised $53 million on the public markets. Karen Tkach Tuzman Point Biopharma Inc. Aktis Oncology Fusion Pharmaceuticals Inc. RayzeBio Inc. Actinium...
BioCentury | Mar 18, 2021
Emerging Company Profile

Through Aktis, MPM bets on radiotherapy for solid tumors

...demand to do another round, even before getting into patients.”A surge of investor appetite enabled competitor RayzeBio Inc....
...Crossover, Novartis AG (NYSE:NVS; SIX:NOVN), Bristol Myers Squibb Co. (NYSE:BMY)CEO: Matthew RodenPatents: Undisclosed Karen Tkach Tuzman MPM Capital RayzeBio Inc. atkis...
BioCentury | Mar 17, 2021
Management Tracks

High-profile departures at Sage, bluebird as Cloonan, Davidson depart; plus CBC Group, Turning Point, Agilent, Intercept, Centessa, Beam and more

...CEO and a member of board. Most recently Knickerbocker cofounded and served as CEO at RayzeBio Inc....
BioCentury | Jan 8, 2021
Finance

Venrock stays modest with $450M ninth fund as it continues to seek disruptive, early-stage tech

...will be allocated to healthcare, and the remainder to technology. Recent therapeutics investments include targeted radiotherapy play RayzeBio Inc....
BioCentury | Dec 18, 2020
Product Development

2021 Predictions: a BioCentury survey

...also garnered substantial investor interest. This month, RayzeBio Inc....
BioCentury | Dec 12, 2020
Finance

RayzeBio gets unexpected lift from broad investor appetite for targeted radiotherapies

...Capital.Versant’s Jerel Davis said the firm scouted radiotherapy opportunities for three years before investing in RayzeBio Inc. Versant...
...operations.Bong Koh, the lead investor from Venrock Healthcare Capital Partners, is joining RayzeBio’s board. Karen Tkach Tuzman RayzeBio Inc. radiophramaceuticals radiotherapy targeted...
BioCentury | Oct 15, 2020
Emerging Company Profile

RayzeBio pulling together radiotherapy platform with $45 million

...Song told BioCentury he was drawn to RayzeBio Inc....
Items per page:
1 - 7 of 7